These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35645118)
1. Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial. Zhang X; Chen J; Liu N; Wang Q; Wu Q; Gao F; Sang Y; Wang P J Cancer Res Ther; 2022 Apr; 18(2):482-487. PubMed ID: 35645118 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560 [TBL] [Abstract][Full Text] [Related]
3. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760 [TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079). Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study. Wang J; Zhang J; Gao J; Zhao M; Ma Z Adv Clin Exp Med; 2024 Jun; 33(6):573-581. PubMed ID: 37676100 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer. Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S Front Immunol; 2023; 14():1278573. PubMed ID: 38124737 [TBL] [Abstract][Full Text] [Related]
8. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829 [TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. Li Y; Zeng J; Huang M; An J; Bai P; Wu L; Zhang R Cancer; 2017 Feb; 123(3):420-425. PubMed ID: 27696395 [TBL] [Abstract][Full Text] [Related]
10. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma. Chao L; Liu J; Chen Y; Fan Y; Guo S; Zhang S Thorac Cancer; 2024 Mar; 15(8):622-629. PubMed ID: 38316630 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study. An J; Li X; Wang J; Zhu L; An R; Jiang K; Huang Y; Wang K; Li G; Wang C; Yuan J; Hou X; Yang G; Li J; Wang Q; Zhu J; Wu L Front Immunol; 2023; 14():1142256. PubMed ID: 37153587 [TBL] [Abstract][Full Text] [Related]
13. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Ren S; Chen J; Xu X; Jiang T; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Yang Z; Shi W; Zou J; Zhou C; J Thorac Oncol; 2022 Apr; 17(4):544-557. PubMed ID: 34923163 [TBL] [Abstract][Full Text] [Related]
14. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906 [TBL] [Abstract][Full Text] [Related]
15. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901 [TBL] [Abstract][Full Text] [Related]
16. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH; JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801 [TBL] [Abstract][Full Text] [Related]
17. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993 [TBL] [Abstract][Full Text] [Related]
18. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Sonabend AM; Gould A; Amidei C; Ward R; Schmidt KA; Zhang DY; Gomez C; Bebawy JF; Liu BP; Bouchoux G; Desseaux C; Helenowski IB; Lukas RV; Dixit K; Kumthekar P; Arrieta VA; Lesniak MS; Carpentier A; Zhang H; Muzzio M; Canney M; Stupp R Lancet Oncol; 2023 May; 24(5):509-522. PubMed ID: 37142373 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients]. Gong JF; Lu M; Li J; Li Y; Zhou J; Lu ZH; Wang XC; Li J; Zhang XT; Shen L Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Feb; 46(1):144-8. PubMed ID: 24535367 [TBL] [Abstract][Full Text] [Related]
20. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. Fang Y; Wang L; Xia GH; Shi MQ Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]